Lyra Therapeutics (LYRA) Return on Sales (2021 - 2025)
Lyra Therapeutics (LYRA) has disclosed Return on Sales for 5 consecutive years, with 239.36% as the latest value for Q3 2025.
- On a quarterly basis, Return on Sales fell 17847.0% to 239.36% in Q3 2025 year-over-year; TTM through Sep 2025 was 35.28%, a 10163.0% increase, with the full-year FY2023 number at 40.23%, up 33.0% from a year prior.
- Return on Sales was 239.36% for Q3 2025 at Lyra Therapeutics, down from 40.64% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 8.29% in Q4 2024 to a low of 1292.91% in Q4 2022.
- A 5-year average of 172.65% and a median of 42.2% in 2024 define the central range for Return on Sales.
- Peak YoY movement for Return on Sales: crashed -124266bps in 2022, then soared 118910bps in 2023.
- Lyra Therapeutics' Return on Sales stood at 50.25% in 2021, then tumbled by -2473bps to 1292.91% in 2022, then soared by 92bps to 103.81% in 2023, then skyrocketed by 108bps to 8.29% in 2024, then tumbled by -2989bps to 239.36% in 2025.
- Per Business Quant, the three most recent readings for LYRA's Return on Sales are 239.36% (Q3 2025), 40.64% (Q2 2025), and 46.7% (Q1 2025).